Unicycive Therapeutics (UNCY) Interest Expenses (2020 - 2025)
Unicycive Therapeutics posted quarterly Interest Expenses of $27000.0 for Q4 2025, up 35.0% year-on-year from $20000.0 in Q4 2024, and up 80.0% on a QoQ basis from $15000.0 in Q3 2025.
Unicycive Therapeutics (UNCY) has 6 years of Interest Expenses data on file, last reported at $27000.0 in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses rose 35.0% year-over-year to $27000.0; the trailing twelve-month figure through Mar 2026 stood at $55000.0 (down 16.67% YoY), and the FY2025 full-year result was $71000.0, changed 0.0% from the prior year.
- Interest Expenses for Q4 2025 stood at $27000.0, up from $15000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $321000.0 in Q2 2021 and bottomed at $3000.0 in Q3 2022.
- The 5-year median for Interest Expenses is $18000.0 (2023), against an average of $50352.9.
- The widest annual swing landed in 2021, when Interest Expenses jumped 15950.0%; it then plunged 94.55% in 2022.
- A 5-year view of Interest Expenses shows it stood at $55000.0 in 2021, then slumped by 94.55% to $3000.0 in 2022, then surged by 533.33% to $19000.0 in 2023, then advanced by 5.26% to $20000.0 in 2024, then surged by 35.0% to $27000.0 in 2025.
- The last three Interest Expenses figures came in at $27000.0 (Q4 2025), $15000.0 (Q3 2025), and $13000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Sep 30, 2023 | 18,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Sep 30, 2021 | 55,000.00 |
| Jun 30, 2021 | 321,000.00 |
| Jun 30, 2021 | 321,000.00 |
| Mar 31, 2021 | 252,000.00 |
| Mar 31, 2021 | 252,000.00 |
| Dec 31, 2020 | 163,000.00 |
| Dec 31, 2020 | 163,000.00 |
| Sep 30, 2020 | 76,000.00 |
| Sep 30, 2020 | 76,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |